Boule Diagnostics Zukünftiges Wachstum
Future Kriterienprüfungen 4/6
Boule Diagnostics wird ein jährliches Gewinn- und Umsatzwachstum von 36.9% bzw. 6% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 37.1% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 8.8% betragen.
Wichtige Informationen
36.9%
Wachstumsrate der Gewinne
37.1%
EPS-Wachstumsrate
| Medical Equipment Gewinnwachstum | 27.0% |
| Wachstumsrate der Einnahmen | 6.0% |
| Zukünftige Eigenkapitalrendite | 8.8% |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | 30 Jul 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Boule Diagnostics AB (publ) Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts
Jul 25
Results: Boule Diagnostics AB (publ) Exceeded Expectations And The Consensus Has Updated Its Estimates
May 10Recent updates
Boule Diagnostics AB (publ) Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts
Jul 25Capital Allocation Trends At Boule Diagnostics (STO:BOUL) Aren't Ideal
Jul 24Sentiment Still Eluding Boule Diagnostics AB (publ) (STO:BOUL)
Jun 06Results: Boule Diagnostics AB (publ) Exceeded Expectations And The Consensus Has Updated Its Estimates
May 10Boule Diagnostics AB (publ) (STO:BOUL) Shares Could Be 47% Below Their Intrinsic Value Estimate
Mar 20Here's What Analysts Are Forecasting For Boule Diagnostics AB (publ) (STO:BOUL) After Its Yearly Results
Feb 09Boule Diagnostics AB (publ) (STO:BOUL) Screens Well But There Might Be A Catch
Dec 30Investors Could Be Concerned With Boule Diagnostics' (STO:BOUL) Returns On Capital
Jul 25Boule Diagnostics AB (publ) (STO:BOUL) Shares Could Be 49% Below Their Intrinsic Value Estimate
May 26Boule Diagnostics' (STO:BOUL) Solid Profits Have Weak Fundamentals
Jul 26Returns On Capital Signal Tricky Times Ahead For Boule Diagnostics (STO:BOUL)
Jul 19We Think Boule Diagnostics (STO:BOUL) Can Stay On Top Of Its Debt
Mar 06Investors Could Be Concerned With Boule Diagnostics' (STO:BOUL) Returns On Capital
Feb 03The Returns At Boule Diagnostics (STO:BOUL) Aren't Growing
Apr 29Should You Investigate Boule Diagnostics AB (publ) (STO:BOUL) At kr67.70?
Apr 09Boule Diagnostics AB (publ) (STO:BOUL) Shares Could Be 27% Below Their Intrinsic Value Estimate
Mar 25Consider This Before Buying Boule Diagnostics AB (publ) (STO:BOUL) For The 1.0% Dividend
Mar 07Is Boule Diagnostics' (STO:BOUL) 210% Share Price Increase Well Justified?
Feb 17
These 4 Measures Indicate That Boule Diagnostics (STO:BOUL) Is Using Debt Extensively
Jan 30Is Boule Diagnostics AB (publ)'s (STO:BOUL) Shareholder Ownership Skewed Towards Insiders?
Jan 14How Many Boule Diagnostics AB (publ) (STO:BOUL) Shares Did Insiders Buy, In The Last Year?
Dec 28Boule Diagnostics AB (publ) (STO:BOUL) Shares Could Be 47% Below Their Intrinsic Value Estimate
Dec 10What Do The Returns On Capital At Boule Diagnostics (STO:BOUL) Tell Us?
Nov 22Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2026 | 654 | 52 | 33 | 72 | 2 |
| 12/31/2025 | 605 | 45 | 20 | 59 | 2 |
| 12/31/2024 | 569 | 25 | -15 | 77 | 2 |
| 6/30/2024 | 573 | 21 | -7 | 83 | N/A |
| 3/31/2024 | 576 | 27 | -15 | 73 | N/A |
| 12/31/2023 | 571 | 25 | -31 | 51 | N/A |
| 9/30/2023 | 572 | 19 | -43 | 36 | N/A |
| 6/30/2023 | 558 | 17 | -81 | -8 | N/A |
| 3/31/2023 | 559 | 16 | -91 | -19 | N/A |
| 12/31/2022 | 548 | 13 | -86 | -11 | N/A |
| 9/30/2022 | 539 | 27 | -87 | -13 | N/A |
| 6/30/2022 | 525 | 32 | -56 | 14 | N/A |
| 3/31/2022 | 495 | 28 | -32 | 29 | N/A |
| 12/31/2021 | 463 | 23 | -13 | 43 | N/A |
| 9/30/2021 | 416 | -27 | 3 | 57 | N/A |
| 6/30/2021 | 403 | -13 | 14 | 64 | N/A |
| 3/31/2021 | 383 | -55 | 25 | 73 | N/A |
| 12/31/2020 | 400 | -48 | 29 | 75 | N/A |
| 9/30/2020 | 437 | -8 | 26 | 70 | N/A |
| 6/30/2020 | 470 | -8 | 29 | 76 | N/A |
| 3/31/2020 | 499 | 35 | 26 | 73 | N/A |
| 12/31/2019 | 499 | 38 | 6 | 54 | N/A |
| 9/30/2019 | 476 | 32 | -14 | 41 | N/A |
| 6/30/2019 | 456 | 21 | -37 | 16 | N/A |
| 3/31/2019 | 444 | 36 | -59 | 11 | N/A |
| 12/31/2018 | 424 | 41 | -42 | 23 | N/A |
| 9/30/2018 | 425 | 48 | -13 | 40 | N/A |
| 6/30/2018 | 424 | 60 | 4 | 51 | N/A |
| 3/31/2018 | 421 | 43 | N/A | 46 | N/A |
| 12/31/2017 | 428 | 37 | N/A | 58 | N/A |
| 9/30/2017 | 422 | 31 | N/A | 45 | N/A |
| 6/30/2017 | 421 | 28 | N/A | 38 | N/A |
| 3/31/2017 | 419 | 38 | N/A | 32 | N/A |
| 12/31/2016 | 397 | 36 | N/A | 20 | N/A |
| 9/30/2016 | 383 | 36 | N/A | 20 | N/A |
| 6/30/2016 | 364 | 22 | N/A | 28 | N/A |
| 3/31/2016 | 341 | 15 | N/A | 29 | N/A |
| 12/31/2015 | 331 | 15 | N/A | 22 | N/A |
| 9/30/2015 | 333 | 29 | N/A | 22 | N/A |
| 6/30/2015 | 318 | 33 | N/A | 8 | N/A |
| 3/31/2015 | 309 | 33 | N/A | 21 | N/A |
| 12/31/2014 | 307 | 30 | N/A | 31 | N/A |
| 9/30/2014 | 289 | 14 | N/A | 16 | N/A |
| 6/30/2014 | 285 | -68 | N/A | 35 | N/A |
| 3/31/2014 | 287 | -64 | N/A | 23 | N/A |
| 12/31/2013 | 277 | -70 | N/A | 16 | N/A |
| 9/30/2013 | 281 | -65 | N/A | 15 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: BOULDas prognostizierte Gewinnwachstum (21.7% pro Jahr) liegt über der Sparquote (1%).
Ertrag vs. Markt: BOULDie Erträge des Unternehmens (21.7% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Swedish (14.1% pro Jahr).
Hohe Wachstumserträge: BOULEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.
Einnahmen vs. Markt: BOULDie Einnahmen des Unternehmens (5.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Swedish (1.9% pro Jahr).
Hohe Wachstumseinnahmen: BOULDie Einnahmen des Unternehmens (5.3% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: BOULDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (8.8%).